Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

1.99
+0.08004.19%
Post-market: 1.93-0.0600-3.02%16:59 EST
Volume:465.67K
Turnover:904.43K
Market Cap:58.91M
PE:-0.86
High:2.00
Open:1.94
Low:1.82
Close:1.91
52wk High:3.84
52wk Low:1.58
Shares:29.61M
Float Shares:21.83M
Volume Ratio:0.70
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3100
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.29
PE(LYR):-0.84

Loading ...

Company Profile

Company Name:
NRX Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
- -
Office Location:
1201 Orange Street,Suite 600,Wilmington,Delaware,United States
Zip Code:
19801
Fax:
- -
Introduction:
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Directors

Name
Position
Jonathan C. Javitt
Chairman, Interim Chief Executive Officer and Chief Scientist
Chaim Hurvitz
Director
Dennis McBride
Director
Michael Taylor
Director
Patrick J. Flynn
Director

Shareholders

Name
Position
Jonathan C. Javitt
Chairman, Interim Chief Executive Officer and Chief Scientist
Joseph M. Casper
Chief Operating Officer
Michael Abrams
Chief Financial Officer and Treasurer
Matthew Duffy
Chief Business Officer
Riccardo Panicucci
Chief Manufacturing and Technology Officer